- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Differentiated thyroid cancer (DTC)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meetings - (PDF 1.7MB)
- Public Summary Document (PSD) November 2023 PBAC Meetings - (Word 865KB)
Cabozanitib – November 2023
Cabozantinib: Tablet 20 mg, Tablet 40 mg, Tablet 60 mg: Cabometyx®
Last updated
15 March 2024